Hepatic Disease Associated With Pregnancy

Slide 1 · Hepatic Disease Associated

With Pregnancy

Clinicopathologic mechanisms, morphology and syndromic distinctions

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Classify pregnancy-associated hepatic dysfunction into infections and pregnancy-specific syndromes.

Link characteristic hepatic lesions to preeclampsia/eclampsia, HELLP syndrome and acute fatty liver.

Contrast the clinical patterns of acute fatty liver and intrahepatic cholestasis.

Recognize signals of severe maternal disease and pregnancy-related fetal risk.

Slide 3 · Two pathways to hepatic disease in pregnancy

Concurrent or exacerbated disease

Viral hepatitis; Opportunistic or systemic infections involving the liver.

Pregnancy-specific disorders

Preeclampsia/eclampsia with HELLP; Acute fatty liver; Intrahepatic cholestasis.

The gestational context changes both the differential diagnosis and the clinical consequences.

Slide 4 · Frequency does not equal severity

3%–5%

Pregnancies with abnormal liver tests; Most findings have little clinical importance.

~0.1%

Pregnancies with serious hepatic complications in the Robbins overview.

Use these textbook estimates as context, not as stand-alone diagnostic probabilities.

Slide 5 · Clinical reasoning begins with the phenotype

Hepatic finding

Abnormal enzymes, jaundice or symptoms

Context

Gestation; Maternal symptoms; Coexistent systemic disease

Syndrome

Infection, hypertensive injury, steatosis or cholestasis

The same laboratory abnormality may result from distinct pathologic processes.

Slide 6 · Liver injury mechanisms are heterogeneous

Infectious mechanisms

Hepatotropic viruses may produce jaundice.

HSV may cause acute hepatic failure.

Listeria may disseminate from infected placental tissue.

Pregnancy-associated mechanisms

Sinusoidal fibrin and hemorrhagic injury in preeclampsia.

Fetoplacental metabolites associated with microvesicular steatosis.

Canalicular bile retention in cholestasis.

Slide 7 · Abnormal liver tests require context

Abnormal testing in pregnancy is not synonymous with severe hepatopathy.

Severe disorders constitute a much smaller subgroup than all biochemical abnormalities.

Symptoms, timing, liver injury mechanism and systemic manifestations help frame interpretation.

A severe clinical syndrome cannot be excluded merely because an initial abnormality appears modest.

Slide 8 · Infections in the maternal hepatic differential

Viral hepatitis

HAV, HBV, HCV and HBV with HDV are named in the Robbins overview.

Hepatitis E

The viral infection singled out for pregnancy-related severity.

Other infections

HSV hepatitis and placentally associated Listeria infection.

Slide 9 · Viral hepatitis: Leading infectious context

Viral hepatitis as the most common cause of jaundice during pregnancy.

The listed infections include hepatitis A, B and C and HBV with HDV coinfection.

Pregnancy does not uniformly worsen the course of each viral hepatitis.

Hepatitis E is distinguished by substantially increased maternal fatality risk.

Slide 10 · Hepatitis E is the high-risk exception

Maternal HEV

Hepatitis E virus infection

Pregnancy context

Clinical course can be altered

Severe outcome

Textbook fatality estimate approaching 20%

The source states that the reason for this pregnancy-specific severity remains unknown.

Slide 11 · Interpreting the HEV risk statement

What Robbins supports

HEV is singled out as pregnancy-sensitive.

A fatality estimate approaching 20% is cited.

Mechanistic explanation is described as unknown.

What the source does not establish

A universal risk for every population or outbreak.

A verified molecular explanation for maternal susceptibility.

A patient-specific prediction from pregnancy status alone.

Slide 12 · HSV hepatitis: An uncommon catastrophic presentation

Herpes simplex virus can involve the liver during pregnancy.

The source characterizes HSV hepatitis as a rare cause of acute liver failure.

Its clinical significance derives from the potential severity, not its prevalence.

Infectious causes remain relevant even when pregnancy-specific disorders are suspected.

Slide 13 · Listeria: An infection with a placental route

Placental tissue

A niche favoring Listeria monocytogenes

Hematogenous spread

Organism may disseminate from the placenta

Hepatic lesion

Liver abscess can result

The maternal liver lesion reflects systemic/placental infection, not a primary pregnancy metabolic syndrome.

Slide 14 · Infectious etiologies: Discriminating emphasis

Viral hepatitis

Principal infectious setting for gestational jaundice.

HEV deserves specific attention to increased severity.

HSV is rare but can produce acute liver failure.

Listerial disease

The placenta provides a favorable tissue environment.

Dissemination may seed the maternal liver.

A hepatic abscess differs morphologically from diffuse hepatocyte injury.

Slide 15 · Case: Infectious liver involvement

A pregnant patient presents with jaundice and suspected acute infectious hepatitis.

Observed findings

Hepatotropic viruses remain a leading category.

One viral infection is specifically associated with worse maternal outcomes.

Pregnancy alone does not explain the exact viral etiology.

Diagnostic task

Which infectious diagnosis must be singled out for pregnancy-associated severity?

Slide 16 · Case interpretation: Prioritize HEV as a concern

The case cannot establish an infectious diagnosis without etiologic evaluation.

Robbins specifically singles out HEV among hepatitis viruses for a pregnancy-altered course.

HSV and Listeria are distinct, less common causes of potentially serious hepatic involvement.

Risk recognition and etiologic confirmation are separate clinical tasks.

Slide 17 · Hypertensive pregnancy disorders and the liver

Preeclampsia

Maternal hypertension with systemic and hepatic manifestations.

Eclampsia

Convulsions occur in the hypertensive disorder, potentially with severe hepatic injury.

HELLP

Hemolysis, elevated liver enzymes and low platelets.

Slide 18 · Preeclampsia: The multisystem setting

The Robbins description includes maternal hypertension, proteinuria and peripheral edema.

Coagulation abnormalities can accompany the disorder.

A frequency of up to 10% of pregnancies.

Hepatic injury can be clinically overt or comparatively subclinical.

Slide 19 · Eclampsia denotes neurologic escalation

Hyperreflexia and convulsions distinguish eclampsia description.

The condition may be life-threatening.

Hepatic involvement may add hemorrhagic and vascular complications.

Neurologic and hepatic severity need not appear in an identical sequence.

Slide 20 · HELLP makes liver injury part of the syndrome

H — Hemolysis

Red-cell destruction is the hematologic component.

EL — Elevated liver enzymes

Biochemical manifestation of hepatic injury.

LP — Low platelets

Thrombocytopenia accompanying the syndrome.

Hepatic abnormalities may be the predominant manifestation of preeclampsia.

Slide 21 · Why hepatic preeclampsia may be overlooked

The maternal liver may be involved before striking clinical liver symptoms appear.

Biochemical changes can be modest or marked.

HELLP combines hepatic injury with hematologic abnormalities.

Serious hepatic complications can evolve despite initially subtle findings.

Slide 22 · The periportal lesion: Vascular injury to necrosis

Periportal sinusoid

Fibrin deposition

Space of Disse

Hemorrhage extends outward

Hepatocyte injury

Periportal coagulative necrosis

This is a periportal microvascular injury pattern in the source, not the centrilobular congestion pattern of cardiac failure.

Slide 23 · Periportal fibrin deposition: Morphology

Simplified schematic — not histologic tissue

Periportal sinusoidal lumen

Fibrin deposits

What it means

Microvascular fibrin and hemorrhage precede periportal hepatocyte necrosis.

Slide 24 · Space of Disse hemorrhage: An injury bridge

Sinusoidal blood compartment

Fibrin-containing sinusoid

Blood in space of Disse

Adjacent periportal hepatocyte injury

Morphologic sequence

Sinusoidal fibrin is intravascular.

Hemorrhage extends beyond the lumen.

Hepatocytes develop coagulative necrosis.

Slide 25 · Periportal coagulative necrosis

Hepatocyte necrosis follows fibrin deposition and perisinusoidal hemorrhage.

The anatomic emphasis is periportal, surrounding portal regions of the lobule.

Coagulative necrosis denotes cell death with temporary retention of tissue architecture.

The vascular distribution helps explain the hepatic injury pattern.

Slide 26 · Periportal injury versus passive congestion

Preeclampsia-associated change

Periportal sinusoidal fibrin.

Hemorrhage into the space of Disse.

Periportal coagulative necrosis.

Passive hepatic congestion

Dilated centrilobular sinusoids.

Congestion and atrophy of pericentral hepatocytes.

A distinct hemodynamic cause and zonal pattern.

These are different vascular mechanisms discussed in the same Robbins chapter.

Slide 27 · Progression to a hepatic hematoma

Severe eclampsia

Intrahepatic hemorrhage

Expansion

Foci of blood coalesce

Hematoma

Blood dissects within hepatic tissue

Progressive hemorrhage can be clinically catastrophic rather than simply biochemical.

Slide 28 · Glisson capsule: The danger of subcapsular blood

Liver parenchyma

Subcapsular blood

Conceptual cutaway — not a specimen

Pathologic consequence

Blood tracks beneath Glisson capsule.

Tension may culminate in hepatic rupture.

Rupture represents a potentially fatal event.

Slide 29 · Hepatic rupture is a vascular emergency

The source describes subcapsular hematoma dissecting under Glisson capsule.

Rupture is a possible endpoint of severe hemorrhagic hepatic injury.

The pathology is not equivalent to uncomplicated elevation of aminotransferases.

A severe clinical presentation warrants immediate specialist obstetric assessment.

Severity distinction

Hepatic rupture is a complication of severe disease, not a routine finding.

Slide 30 · Aminotransferases indicate hepatocellular injury

Preeclampsia-related hepatic involvement may elevate serum aminotransferases.

A range from modest to severe elevation.

Enzyme release reflects hepatocyte injury but does not by itself define its cause.

Interpret biochemistry alongside hypertensive and hematologic manifestations.

Slide 31 · Bilirubin changes may be comparatively mild

Mild serum bilirubin elevation in hepatic preeclampsia.

Severe aminotransferase elevation does not require proportionately severe jaundice.

The vascular and hemorrhagic mechanisms remain clinically important.

Bilirubin and aminotransferases report different dimensions of hepatic dysfunction.

Slide 32 · Coagulopathy marks advanced hepatic involvement

Liver injury

Hepatic dysfunction becomes severe

Systemic effect

Coagulation becomes impaired

Clinical meaning

Advanced, potentially lethal disease

The textbook explicitly flags hepatic dysfunction sufficient to cause coagulopathy as ominous.

Slide 33 · Preeclampsia: Severity determines intervention

Milder hepatic involvement

Conservative management as possible.

Biochemical severity and symptoms require monitoring.

Maternal and fetal status determine the actual clinical plan.

Severe hepatic involvement

The source specifies pregnancy termination in severe cases.

Hemorrhage, hematoma and coagulopathy indicate high risk.

Requires coordinated clinical management.

These are pathology teaching principles; No obstetric management protocol is specified in the source.

Slide 34 · Maternal course after surviving preeclampsia

According to the textbook, survivors of mild or severe preeclampsia recover without hepatic sequelae.

That recovery statement does not minimize risk during acute severe illness.

Resolution of the pregnancy-associated process differs from irreversible chronic liver disease.

The immediate hazard is the potentially life-threatening complication phase.

Slide 35 · Acute fatty liver of pregnancy: Core features

Uncommon

Approximately 1 in 16,000 pregnancies in the Robbins estimate.

Late pregnancy

Usually arises during the third trimester.

Potentially severe

May progress rapidly to liver failure, coma and death.

Slide 36 · AFLP spans a spectrum of severity

Acute fatty liver of pregnancy may be subclinical or initially modest.

Aminotransferase elevation may be the first biochemical signal.

At the severe end are hepatic failure, coma and death.

Rapid progression over days makes initial apparent mildness potentially deceptive.

Slide 37 · AFLP: Gestational timing and progression

Second half

Usual period of onset

Third trimester

Most typical presentation

Within days

Possible sharp deterioration

End of pregnancy

Primary treatment in source

This schematic emphasizes a possible course, not an inevitable progression.

Slide 38 · AFLP and disordered fatty acid metabolism

The source links some cases to inherited deficiency of mitochondrial long-chain fatty-acid oxidation.

The implicated enzyme is long-chain 3-hydroxyacyl-CoA dehydrogenase.

The fetal–placental unit is central to the proposed maternal injury pathway.

This mechanism is described for a subset, not all AFLP cases.

Slide 39 · Inheritance creates a fetal enzymatic deficit

Maternal carrier

One altered allele

Paternal carrier

One altered allele

Affected offspring: Two altered alleles; Enzyme deficiency

Familial mechanism in a subset of cases; The parental carrier states are independent inputs.

Slide 40 · The fetal–placental metabolic link

Fetal enzyme deficiency

Impaired long-chain 3-hydroxyacyl-CoA metabolism

Fetal/placental products

Long-chain 3-hydroxyacyl metabolites

Maternal exposure

Metabolites enter maternal circulation

The fetus and placenta may remain clinically well while maternal hepatic dysfunction develops.

Slide 41 · Maternal hepatotoxicity: Proposed pathway

Fetoplacental metabolites

Excess long-chain hydroxylacyl intermediates

Transfer

Entry into maternal bloodstream

Maternal liver

Toxic stress with hepatocyte fat accumulation

This as an unusual example of fetal metabolism producing maternal disease.

Slide 42 · Genetic mechanism: Interpret the limits

Supported causal model

Both parents carry a relevant mutant allele.

An affected fetus lacks enzyme function.

Metabolites of fetoplacental origin injure the mother.

Important limitations

The textbook says this occurs in a subset.

Do not infer carrier status in every patient.

The model does not explain all pregnancy-related steatosis.

Slide 43 · Microvesicular steatosis: The histologic hallmark

Conceptual hepatocyte schematic — not H&E microscopy

Diagnostic morphology

Numerous small cytoplasmic lipid droplets distributed diffusely among hepatocytes.

Slide 44 · Severe AFLP: Additional histologic abnormalities

Diffuse microvesicular hepatocellular steatosis is the characteristic finding.

More severe cases may show lobular disarray and hepatocyte dropout.

Collapse of the reticulin framework can accompany loss of hepatocytes.

Portal tract inflammation may be present.

Slide 45 · AFLP morphology overlaps with other injuries

Characteristic AFLP features

Diffuse microvesicular steatosis.

Hepatocyte dropout and reticulin collapse in severe cases.

Cholestasis may coexist.

Why viral hepatitis may be confused

Severe AFLP can show lobular disarray.

Portal inflammation and hepatocyte loss are not unique to AFLP.

Tissue findings require clinical and gestational context.

Slide 46 · Cholestasis can accompany acute fatty liver

The Robbins morphology description notes possible accompanying cholestasis.

Bile retention is not exclusive to intrahepatic cholestasis of pregnancy.

The dominant AFLP lesion remains diffuse microvesicular steatosis.

Coexisting cholestasis must be interpreted within the full lesion pattern.

Slide 47 · Case: An evolving AFLP phenotype

A patient in the third trimester develops nausea, jaundice and bleeding.

Observed findings

Symptoms arise late in pregnancy.

A liver injury syndrome progresses over days.

Microvesicular steatosis is the characteristic histologic lesion.

Diagnostic task

What disease mechanism links a fetal–placental metabolic process to maternal hepatopathy?

Slide 48 · AFLP: Maternal clinical manifestations

Nausea and vomiting may accompany evolving hepatic dysfunction.

Jaundice reflects impaired bilirubin handling.

Bleeding is a serious manifestation consistent with hepatic failure.

At the extreme, encephalopathic coma and death can occur.

Slide 49 · AFLP may deteriorate rapidly

Early dysfunction

Symptoms or aminotransferase rise

Escalation

Progressive hepatic failure

Critical illness

Bleeding, coma or death

Not every patient follows this trajectory; Rapid evolution is the warning emphasized by Robbins.

Slide 50 · AFLP can overlap clinically with preeclampsia

20%–40%

Presenting symptoms may be those of coexistent preeclampsia.

Shared clinical setting

Late-pregnancy systemic illness with biochemical hepatic injury.

Different lesions

AFLP: Microvesicular steatosis; Preeclampsia: Periportal microvascular hemorrhagic injury.

Slide 51 · AFLP: Intervention follows the pregnancy link

The source identifies termination of pregnancy as the primary treatment.

This recommendation follows the fetal–placental contribution to maternal toxic exposure.

AFLP requires recognition as a potentially fast-progressing systemic emergency.

The textbook excerpt does not specify delivery timing protocols or drug regimens.

Slide 52 · Intrahepatic cholestasis of pregnancy

Core symptom

New-onset pruritus in the second or third trimester.

Biochemical pattern

Marked bile-salt elevation; Bilirubin may rise mildly.

Natural history

Usually resolves within 2–3 weeks after delivery.

Slide 53 · ICP: Symptom sequence and resolution

Second/third trimester

Onset of pruritus

Later symptoms

Dark urine ± pale stools/jaundice

Delivery

Gestational trigger ends

2–3 weeks later

Typical resolution

The temporal relationship is diagnostically informative.

Slide 54 · Pruritus is the clinical hallmark of ICP

Pruritus commonly begins during the second or third trimester.

The itching to retention of bile salts.

The itching may be intensely distressing despite relatively limited jaundice.

Severity of maternal pruritus and magnitude of bilirubin elevation are distinct features.

Slide 55 · Additional cholestatic symptoms

Dark urine follows pruritus in approximately 10%–25% of cases in the source.

Light-colored stools may occur occasionally.

Jaundice may occur but is not required for the typical pruritic presentation.

These findings reflect altered biliary excretion rather than vascular necrosis.

Slide 56 · ICP biochemistry: Bile salts versus bilirubin

Bile salts

Serum bile salts are markedly increased.

Retention is linked to pruritus.

The bile salt abnormality is central to the syndrome.

Bilirubin / alkaline phosphatase

Bilirubin elevation is mostly conjugated.

Bilirubin rarely exceeding 5 mg/dL.

Alkaline phosphatase may be slightly increased.

Slide 57 · ICP pathogenesis: Interacting susceptibilities

Gestational hormones

Altered endocrine milieu of pregnancy.

Environmental influences

Non-genetic susceptibility.

Transporter defects

Impaired proteins involved in bile export.

Together these factors may engender canalicular cholestasis; No single universal cause is specified.

Slide 58 · Canalicular bile retention: Conceptual model

Hepatocyte

Bile canaliculus

Transport impairment

Conceptual transport model — not tissue image

Consequence

Bile constituents accumulate when canalicular export is impaired.

Slide 59 · ICP: Pregnancy-related and transport-related factors

Altered hormonal state is a proposed contributor to gestational cholestasis.

Environmental factors also contribute in the model presented by Robbins.

Defects involving transporter proteins are implicated in susceptibility.

Their interaction produces canalicular cholestasis rather than diffuse steatosis.

Slide 60 · ICP outcome: Maternal burden and fetal concern

Maternal symptom burden

Bile-salt-associated pruritus may be exceptionally distressing.

Fetal concern

The source describes a modest risk of fetal loss.

Resolution

The maternal cholestatic syndrome commonly abates postpartum.

Slide 61 · ICP resolves after delivery—but may recur

Resolution typically within two to three weeks following delivery.

A subsequent pregnancy may precipitate recurrence.

The pregnancy dependency supports a hormonal and transporter interaction.

Resolution of maternal symptoms does not negate the described fetal risk.

Slide 62 · Three pregnancy-associated hepatic syndromes

Dimension

Preeclampsia / HELLP

Acute fatty liver

Intrahepatic cholestasis

Typical context

Hypertensive pregnancy syndrome

Usually third trimester

Second or third trimester

Dominant process

Periportal vascular injury

Microvesicular steatosis

Canalicular cholestasis

Major danger

Hematoma, rupture, coagulopathy

Rapid hepatic failure

Fetal loss; Maternal pruritus

Notable association

HELLP / eclampsia

May coexist with preeclampsia

May recur in later pregnancies

Slide 63 · Biochemical and morphologic discrimination

Feature

Preeclampsia / HELLP

AFLP

ICP

Hepatic enzymes

Mild to marked rise

Rise may be modest or severe

Source emphasizes bile salts

Hepatic morphology

Periportal fibrin / necrosis

Diffuse microvesicular fat

Canalicular cholestasis

Other defining clue

Hypertension / hemolysis / platelets

Failure, bleeding, GI symptoms

Pruritus; Bilirubin usually modest

Severe outcome

Coagulopathy or rupture

Coma and death

Fetal loss risk

Slide 64 · Different mechanisms can converge on jaundice

Infectious cause

Viral hepatitis and hepatocyte injury.

Metabolic or vascular cause

Acute fatty liver or preeclamptic hepatic injury.

Cholestatic cause

Canalicular retention of bile constituents.

These are alternative etiologic categories—not sequential steps in one pathway.

Slide 65 · Diagnostic exercise: Pruritus predominates

A pregnant patient develops intense itching in the third trimester.

Observed findings

Bile salts are markedly elevated.

Bilirubin is only mildly increased.

The syndrome later resolves postpartum.

Diagnostic task

Which pregnancy-related liver syndrome best fits this pattern?

Slide 66 · Diagnostic exercise: Hematologic clues predominate

A pregnant patient develops hypertension and liver enzyme elevation.

Observed findings

Hemolysis and thrombocytopenia are present.

Hepatic injury may initially be subclinical.

Severe disease can cause periportal hemorrhagic injury.

Diagnostic task

Which named syndrome organizes these findings?

Slide 67 · Diagnostic exercise: Microvesicular change

A third-trimester patient develops progressive vomiting, jaundice and bleeding.

Observed findings

The deterioration is rapid.

Hepatocytes contain diffuse microvesicular fat.

A fetoplacental mitochondrial oxidation mechanism is possible.

Diagnostic task

What diagnosis and specific pathogenesis are suggested?

Slide 68 · Integrated case answers

Presentation

Favored interpretation

Discriminating source feature

Pruritus + bile salts

Intrahepatic cholestasis

Canalicular retention; Postpartum resolution

Hemolysis + low platelets

HELLP / preeclampsia

Periportal fibrin and hemorrhagic injury

Late severe disease + microvesicular fat

Acute fatty liver

Fetoplacental metabolism in a subset

Slide 69 · Mechanism-driven synthesis

Vascular injury

Fibrin and hemorrhage → periportal necrosis.

Metabolic toxicity

Fetoplacental metabolites → microvesicular steatosis.

Transport dysfunction

Bile retention → pruritus.

Independent mechanisms; Infection is an additional major category when jaundice presents.

Slide 70 · Final clinicopathologic priorities

Pregnancy-associated hepatic dysfunction has infectious, vascular, metabolic and cholestatic causes.

Preeclampsia/HELLP: Periportal fibrin, hemorrhage and possible necrosis or rupture.

AFLP: Diffuse microvesicular steatosis and potentially rapid hepatic failure.

ICP: Pruritus, bile-salt elevation, postpartum resolution and fetal risk.

Critical clinical decisions require obstetric and hepatology assessment beyond this pathology overview.

Slide 71 · Primary source and scope

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition (2026).

Chapter 18: Liver and Gallbladder, printed pages 786–787.

Sections: Hepatic Disease Associated With Pregnancy; Preeclampsia and Eclampsia; Acute Fatty Liver of Pregnancy; Intrahepatic Cholestasis of Pregnancy.

The lecture reflects the supplied textbook excerpt rather than an updated clinical practice guideline.